Oncology

This continuing education activity addresses the factors that increase and decrease a woman's risk for breast cancer, and includes information for pharmacists to help provide evidence-based counseling on preventative measures.

The FDA approved Genentech, Inc's pertuzumab injection (Perjeta) for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Girls who received mantle radiation for childhood cancer were found to be at elevated risk for secondary breast cancer later in life.

Afatinib shows promise as a treatment for patients with advanced lung adenocarcinomas who tested positive for EGFR mutations.

As industry invests billions into self-administered oncolytics, specialty pharmacy steps in. This special issue focuses on the cutting-edge, real-world practices and successes of specialty pharmacy in oncology.

Taking a comprehensive look at the ever-changing and always challenging oncology scene, we present a variety of topics and voices to understand this complex world and the significant impact of specialty pharmacists.

Walgreens Specialty Pharmacy is adding 6 medications to its oral oncology cycle management program, in a significant expansion of the comprehensive treatment and support program it provides to benefit patients, physicians and payers.

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1000 human cancer cell lines used in drug research and development.

Diplomat Specialty Pharmacy's president and chief executive officer shares his thoughts about the turbulent oncology arena and how specialty pharmacists can survive the storm and prosper.

A severe shortage of the key medication for childhood leukemia appears to have been averted, but the problem is likely to reemerge in the future.

A severe shortage of the key medication for childhood leukemia appears to have been averted, but the problem is likely to reemerge in the future.

CVS Caremark is expanding into the realm of specialty oncology management for drugs covered under the medical benefit and traditionally administered in physician offices or clinics.

Pharmacies in the community setting have led the way in patient compliance, but have been largely ignored by MCOs and the pharmaceutical industry.

Instructing patients to take oral anticancer medications without food is a costly, risky move, says pharmacology specialist.

The comprehensive management of oncolytic therapy is only possible with the emergence of oncology pharmacy vendors within a unique distribution channel.